The stock of Sanofi (NASDAQ:SNY) increased by $0.79 on Wednesday to $55.66, up 1.44 percent. The last five days have seen an average of 1,370,979 shares of common stock traded. 18 times new highs were reached in the current year, with a gain of $7.24. The average number of shares traded over the last 20 days was 1,112,475, while the average volume over the last 50 days totaled 1,236,274.
SNY stock appreciated 3.63% since last month. On 09/06/23, the company’s shares reached a one-month low of $52.46. The stock touched a high of $57.82 on 04/26/23, after rallying from a low of $36.91 in 52 weeks. The price of SNY stock has risen by 14.93% or $7.24 this year, reaching a new high 18 times. Still, the stock price is down -3.74% from the 52-week high.
Valuation Metrics
Sanofi (SNY) has a trailing price-to-earnings (P/E) ratio of 15.26. Beta for the stock is 0.56. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.89, the price-to-book (PB) ratio of 1.80.
Company paid $1.3770 per share in dividends, a decrease of -23.36% from $1.7968 last year. A $0.4198 dividend decrease was reported on Tuesday May 30 2023.
Financial Health
For the three months ended June 29, Sanofi’s quick ratio was 0.80, while its current ratio was 1.20, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.23, and the total debt to equity ratio is 0.29. As far as profitability goes, gross margin for the trailing twelve months is 69.80% percent. Based on annual data, it had gross profit of $33.39 billion and revenue of $47.82 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a 9.00% return on investment (ROI) in the past year.
Earnings Surprise
According to Sanofi’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $50.84 billion, while revenues rose by 17.67% to $0.0. It was predicted that Sanofi’s quarterly earnings would be $0.95, but it ended up being $1.55, beating the consensus by -38.70%. EBITDA was $2.04 billion for the quarter. At the end of Sanofi’s most recent quarter ended June 29, its liabilities totaled 57.14 billion, while its total debt was $21.03 billion.
Technical Picture
Here’s a quick look at Sanofi’s (SNY) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 70.68%, suggesting the stock is Overbought, with a 13.27% historical volatility rate.
The stochastic %K and %D were 84.41% and 79.32% respectively, while the average true range (ATR) was 0.69. Based on the 14-day stochastic reading of 100.00%, the RSI (14) reading is 65.36%. On the 9-day MACD Oscillator, the stock is at 0.35, and the 14-day reading is at 0.90.
Analyst Ratings
In its most recent analyst report, Berenberg raised its rating on Sanofi (NASDAQ: SNY) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Sanofi (SNY) an Overweight rating. SNY is a stock that is recommended for selling by 2 brokerage firms, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 4 rates it overweight and 13 others recommend it as a buy.
What is SNY’s price target for the next 12 months?
The current consensus forecast for the stock is between $49.66 and $74.97, with a median target price of $62.02. In analyzing these forecasts, the average price target given by analysts for Sanofi (SNY) is $61.74.
